AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the Application.

Deletions are strikethrough and additions are underlined.

Listing of Claims:

1. (Canceled)

The drug kit according to claim 11, wherein the oncolytic virus to 2. (Currently amended)

be infected to the carrier cell has a promoter selected from the group consisting of 1A1.3B

promoter, midkine promoter, β-HCG promoter, SCCA1 promoter, cox-2 promoter, PSA

promoter and a tumor specific promoter according to kind of cancer to be treated.

3. (Currently amended) The drug kit according to claim 11, wherein the virus for

immunological treatment and the oncolytic virus are selected from the group consisting of

adenovirus, herpes virus, lentivirus, HIV virus, retrovirus, reovirus, vesicular stomatitis virus

(VSV) and any other oncolytic virus.

4. (Withdrawn - Currently amended) The drug kit according to claim 11, further comprising a

virus for immunological treatment to be administered for inducing a CTL reaction within the

living body to administration of the carrier cell.

5. (Withdrawn - Currently amended) The drug kit according to claim 11, further comprising

atelocollagen.

6. (Withdrawn - Currently amended) The drug kit according to claim 11, further comprising a

GM-CSF expression vector to be infected to the carrier cell before administration.

2

Appln. No. 10/575,894

Amendment and Response to Non-Final Rejection

7. (Withdrawn - Currently amended) The <u>drug</u> kit according to claim 11, further comprising an iron preparation and/or a porphyrin compound.

8. (Canceled)

9. (Withdrawn – Currently amended) A <u>drug</u> kit comprising a carrier cell for gene therapy in treating cancer including a carrier cell to be infected with an oncolytic virus, so as to make the oncolytic virus act on a tumor cell within a living body, wherein both A549 cell and 293 cell are together used as the carrier cell.

10. (Canceled)

11. (Currently amended) A <u>drug kit for cancer gene therapy therapeutic drug kit comprising:</u>
a tumor cell, <u>which is to be administrated prior to a carrier cell, to induce perform tumor vaccination</u>, and

a carrier cell infected with an oncolytic virus, so as to make the oncolytic virus act on a tumor cell within a living body, wherein the carrier cell is a A549 cell.

3